ATEC

• Total revenue for Q2 2026 was $214 million, a 15% increase year-over-year.
• GAAP net loss was $26 million; non-GAAP net income was $11 million.
• Non-GAAP adjusted EBITDA was $36 million, with margin expanding 420 basis points to 16.8%.
• Company reaffirms 2026 revenue outlook of ~$882 million and raises adjusted EBITDA guidance to ~$140 million.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• At the June 10, 2026 annual meeting, stockholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, effective upon approval.
• Stockholders ratified Deloitte & Touche LLP as independent auditor for fiscal year 2026.
• Non-binding advisory vote on named executive officer compensation passed with 81,927,395 votes for and 12,420,476 against.
• A quorum of 118,373,608 shares was represented at the meeting out of 153,702,057 shares outstanding.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• Proceeds from the new facility, along with cash on hand, were used to repay in full all outstanding obligations under the prior ABL credit agreement and 2023 term loan agreement.
• The new facility matures on the fifth anniversary of closing, with a springing maturity tied to the company's 0.75% convertible senior notes due 2030.
• The company borrowed $175 million under the term loan and $40 million under the revolving credit facility at closing.
• The company also reported first quarter 2026 results: total revenue of $192 million, GAAP net loss of $34 million, and non-GAAP adjusted EBITDA of $21 million.

1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits

• Ward W. Woods notified Alphatec Holdings on Feb. 25, 2026, of his retirement from the Board, effective Feb. 27, 2026, for personal reasons and not due to any disagreement with the company.
• Woods also served on the Board's Compensation Committee.
• On Feb. 26, 2026, the Board reduced its size from eight to seven directors to reflect Woods's resignation.
• The Vesting Acceleration Agreement is filed as Exhibit 10.1 to the 8-K.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• Fourth-quarter 2025 total revenue was $213 million, with GAAP net loss of $22 million and non-GAAP net income of $9 million.
• Full-year 2025 non-GAAP adjusted EBITDA was $93 million (12% margin); Q4 adjusted EBITDA was $33 million (16% margin).
• Company guides FY2026 total revenue to approximately $890 million (17% growth) and raises adjusted EBITDA guidance to ~$134 million (15% of revenue).
• Company expects at least $20 million of free cash flow in FY2026; reported $3 million free cash flow for FY2025.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Fourth-quarter 2025 preliminary total revenue of $212.2M to $213.2M, with surgical revenue of $189.3M to $190.0M and EOS revenue of $22.9M to $23.2M.
• Company reaffirms full-year 2025 adjusted EBITDA guidance of $91 million; cash balance approximated $161 million as of December 31, 2025.
• Full-year 2026 outlook: total revenue of $890 million (surgical ~$805M, EOS ~$85M), adjusted EBITDA of ~$130 million, and free cash flow of ~$20 million.
• Announced acquisition of exclusive U.S. distribution rights for Theradaptive's OsteoAdapt, a next-generation rhBMP-2 biologic in Phase II trials for spinal fusion.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Jeffrey P. Rydin, a member of Alphatec Holdings' Board of Directors, passed away on November 3, 2025, after a lengthy illness.
• He had nearly three decades of experience in medical devices, including senior sales roles at Ellipse Technologies, NuVasive, and DePuy Spine.
• The company issued a press release on November 7, 2025, announcing his passing and expressing condolences.
• The event was reported under Item 8.01 (Other Events) as a non-operational disclosure.

8.01 Other Events · 9.01 Financial Statements and Exhibits

• Surgical revenue grew 31% to $177 million; EOS revenue grew 29% to $20 million.
• GAAP net loss was $29 million; non-GAAP net income was $4 million.
• Adjusted EBITDA was $26 million, a 13% margin, expanding 840 basis points year-over-year.
• Full-year 2025 revenue guidance raised to $760 million (24% growth) and adjusted EBITDA to approximately $91 million.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits